Jump to section

References

Trials

Economics

Properties

Spectra

Taxonomy

Desmopressin

Targets (3)Enzymes (2)Biointeractions (3)

Identification

Name

Desmopressin

Accession Number

DB00035 (BTD00112, BTD00061, BIOD00112, BIOD00061)

Type

Small Molecule

Groups

Approved

Description

Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release from the stimulation of increased plasma osmolarity or decreased circulating blood volume, ADH mainly acts on the cells of the distal part of the nephron and the collecting tubules in the kidney ^[6]. The hormone interacts with V1, V2 or V3 receptors with differing signal cascade systems.

Desmopressin displays enhanced antidiuretic potency, fewer pressor effects due to V2-selective actions, and a prolonged half-life and duration of action compared to endogenous ADH ^[2]. It has been employed clinically since 1972 and is available in various formulations including intranasal solution, intravenous solution, oral tablet and oral lyophilisate ^[3]. Desmopressin is indicated for the treatment of polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus. It was also newly approved for the treatment of mild classical hemophilia and von Willebrand's disease for minor surgeries. The active ingredient in most formulations is desmopressin acetate.

Structure

Similar Structures

Synonyms

1-(3-mercaptopropionic acid)-8-D-arginine-vasopressin
1-deamino-8-D-arginine vasopressin
1-desamino-8-D-arginine vasopressin
dDAVP
Desmopresina
Desmopressine
Desmopressinum

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Desmopressin acetate	1K12647SFC	62288-83-9	MLSVJHOYXJGGTR-IFHOVBQLSA-N
Desmopressin acetate trihydrate	XB13HYU18U	62357-86-2	YNKFCNRZZPFMEX-XHPDKPNGSA-N

Product Images

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Ddavp	Solution	.1 mg/mL	Nasal	Sanofi Aventis	1978-02-21	Not applicable
Ddavp	Injection	4 ug/mL	Intravenous	Ferring Pharmaceuticals	1984-03-30	Not applicable
Ddavp	Tablet	.1 mg/1	Oral	Sanofi Aventis	1995-09-06	Not applicable
Ddavp	Tablet	.1 mg/1	Oral	Ferring Pharmaceuticals	1995-09-06	Not applicable
Ddavp	Injection	4 ug/mL	Intravenous	Ferring Pharmaceuticals	1984-03-30	Not applicable
Ddavp	Solution	4 ug/mL	Intravenous	Sanofi Aventis	1984-03-30	Not applicable
Ddavp	Spray	.1 ug/mL	Nasal	Ferring Pharmaceuticals	1978-02-21	Not applicable
Ddavp	Spray	.1 ug/mL	Nasal	Ferring Pharmaceuticals	1978-02-21	Not applicable
Ddavp	Tablet	.2 mg/1	Oral	Sanofi Aventis	1995-09-06	Not applicable
Ddavp	Tablet	.2 mg/1	Oral	Ferring Pharmaceuticals	1995-09-06	Not applicable

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Desmopressin acetate	Injection	4 ug/mL	Intravenous	Teva Parenteral Medicines, Inc.	1997-11-01	Not applicable
Desmopressin Acetate	Tablet	.2 mg/1	Oral	bryant ranch prepack	2011-08-15	Not applicable
Desmopressin Acetate	Injection, solution	40 ug/10mL	Intravenous; Subcutaneous	Sagent Pharmaceuticals	2018-03-15	Not applicable
Desmopressin Acetate	Tablet	.2 mg/1	Oral	Glenmark Pharmaceuticals Inc.,Usa	2015-05-28	Not applicable
Desmopressin Acetate	Tablet	.2 mg/1	Oral	Heritage	2014-08-14	Not applicable
Desmopressin Acetate	Tablet	.1 mg/1	Oral	Blue Point Laboratories	2017-04-30	Not applicable
Desmopressin Acetate	Tablet	.2 mg/1	Oral	Teva	2006-01-27	2017-12-31
Desmopressin Acetate	Solution	.1 mg/mL	Nasal	Sun Pharma Global FZE	2013-12-24	Not applicable
Desmopressin Acetate	Tablet	.2 mg/1	Oral	Amerincan Health Packaging	2015-09-15	2019-02-28
Desmopressin Acetate	Solution	.1 mg/mL	Nasal	Physicians Total Care, Inc.	2006-05-22	Not applicable

International/Other Brands

Adiuretin (Ferring) / DesmoMelt (Ferring) / Minirin / Stimate

Categories

UNII

ENR1LLB0FP

CAS number

16679-58-6

Weight

Average: 1069.217
Monoisotopic: 1068.426954962

Chemical Formula

C₄₆H₆₄N₁₄O₁₂S₂

InChI Key

NFLWUMRGJYTJIN-NXBWRCJVSA-N

InChI

InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29-,30-,31-,32-,33-,34-/m0/s1

IUPAC Name

(2S)-2-{[(2S)-1-[(4R,7S,10S,13S,16S)-13-benzyl-10-(2-carbamoylethyl)-7-(carbamoylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl]pyrrolidin-2-yl]formamido}-5-carbamimidamido-N-(carbamoylmethyl)pentanamide

SMILES

NC(=O)CC[[email protected]@H]1NC(=O)[[email protected]](CC2=CC=CC=C2)NC(=O)[[email protected]](CC2=CC=C(O)C=C2)NC(=O)CCSSC[[email protected]](NC(=O)[[email protected]](CC(N)=O)NC1=O)C(=O)N1CCC[[email protected]]1C(=O)N[[email protected]@H](CCCNC(N)=N)C(=O)NCC(N)=O

Pharmacology

Indication

Indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void (intranasal).
Indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region (intranasal/parenteral).
Indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5% or mild to moderate classic von Willebrand's Disease (Type I) with factor VIII levels greater than 5% during surgical procedures and postoperatively to maintain hemostasis (parenteral).

Structured Indications

Pharmacodynamics

By mimicking the actions of endogenous ADH, desmopressin acts as a selective agonist of V2 receptors expressed in the renal collecting duct (CD) to increase water re-absorption and reduce urine production. Desmopressin has been shown to be more potent than ADH in increasing plasma levels of factor VIII activity in patients with hemophilia and von Willebrand's disease Type I ^[8]. Desmopressin demonstrates markedly diminished pressor activity. Desmopressin administered intranasally has an antidiuretic effect about one-tenth that of an equivalent dose administered by injection ^[7].

Mechanism of action

Upon binding of desmopressin to V2 receptors in the basolateral membrane of the cells of the distal tubule and collecting ducts of the nephron, adenylyl cyclase is stimulated. The resulting intracellular cascades in the collecting duct lead to increased rate of insertion of water channels, called aquaporins, into the lumenal membrane and enhanced the permeability of the membrane to water ^[6].

Target	Actions	Organism
AVasopressin V2 receptor	agonist	Human
AVasopressin V1a receptor	Not Available	Human
AVasopressin V1b receptor	Not Available	Human

Absorption

Following nasal spray administration of 0.83 mcg and 1.66 mcg, median time to peak plasma concentrations (Tmax) was 0.25 and 0.75 hour, respectively ^{[FDA Label]}. The peak plasma concentration was approximately 4.00 (± 3.85) pg/mL and 9.11 (± 6.90) pg/mL, respectively ^{[FDA Label]}. The bioavailability of 1.5 mg/mL desmopressin administered by the intranasal route was between 3.3 and 4.1% ^[8].

The absolute bioavailability of orally administered desmopressin varies between 0.08% and 0.16% where the mean maximum plasma concentration is reached within 2 hours ^[9].

Volume of distribution

The distribution volume of orally administered desmopressin is 0.2 – 0.32 l/kg ^[9]. It is not reported to cross the blood-brain barrier.

Protein binding

Following radioiodination (125I) in the N-terminal, the fraction of plasma protein binding of desmopressin was reported to be 17.3 ± 1.5% in a pharmacokinetic study involving healthy subjects ^[5].

Metabolism

In vitro, in human liver microsome preparations, it has been shown that no significant amount of desmopressin is metabolised in the liver and thus human liver metabolism in vivo is not likely to occur ^[9].

Route of elimination

Desmopressin is mainly excreted in the urine. About 65% of the amount of desmopressin absorbed after oral administration could be recovered in the urine within 24 hours ^[9].

Half life

Following an intranasal dose of 1.66 mcg of desmopressin, the median apparent terminal half-life was 2.8 hours ^{[FDA Label]}. Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment ^{[FDA Label]}. The oral terminal half life of desmopressin ranges from 2 to 3.11 hours ^[9].

Clearance

Not Available

Toxicity

Intravenous TDLo in humans is reported to be 0.3 µg/kg/10M ^[MSDS]. Desmopressin is associated with hyponatremia in case of overdose, which may require temporary or permanent discontinuation of the therapy depending on severity. The effects of hyponatremia include seizure, altered mental status (confusion, drowsiness or continuing headache), cardiac arrhythmias and worsening edema. Other signs of overdose may include oliguria and rapid weight gain due to fluid retention ^{[FDA Label]}. In case of overdose, reduce the dose or frequency of drug administration, or discontinue use if appropriate. Assessment of serum sodium and initiation of appropriate medical treatment is recommended.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
(4R)-limonene	The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Desmopressin.	Investigational
Aceclofenac	The risk or severity of adverse effects can be increased when Aceclofenac is combined with Desmopressin.	Approved, Investigational
Acemetacin	The risk or severity of adverse effects can be increased when Acemetacin is combined with Desmopressin.	Approved, Experimental, Investigational
Acetylsalicylic acid	The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Desmopressin.	Approved, Vet Approved
Adapalene	The risk or severity of adverse effects can be increased when Adapalene is combined with Desmopressin.	Approved
Alaproclate	The risk or severity of adverse effects can be increased when Alaproclate is combined with Desmopressin.	Experimental
Alclofenac	The risk or severity of adverse effects can be increased when Alclofenac is combined with Desmopressin.	Approved, Withdrawn
Alfentanil	The risk or severity of adverse effects can be increased when Alfentanil is combined with Desmopressin.	Approved, Illicit
Alminoprofen	The risk or severity of adverse effects can be increased when Alminoprofen is combined with Desmopressin.	Experimental
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Desmopressin.	Experimental, Illicit
Alphaprodine	The risk or severity of adverse effects can be increased when Alphaprodine is combined with Desmopressin.	Illicit
Amineptine	The risk or severity of adverse effects can be increased when Amineptine is combined with Desmopressin.	Illicit, Withdrawn
Amitriptyline	The risk or severity of adverse effects can be increased when Amitriptyline is combined with Desmopressin.	Approved
Amoxapine	The risk or severity of adverse effects can be increased when Amoxapine is combined with Desmopressin.	Approved
Andrographolide	The risk or severity of adverse effects can be increased when Andrographolide is combined with Desmopressin.	Investigational
Anisodamine	The risk or severity of adverse effects can be increased when Anisodamine is combined with Desmopressin.	Investigational
Antipyrine	The risk or severity of adverse effects can be increased when Antipyrine is combined with Desmopressin.	Approved, Investigational
Apocynin	The risk or severity of adverse effects can be increased when Apocynin is combined with Desmopressin.	Investigational
Apremilast	The risk or severity of adverse effects can be increased when Apremilast is combined with Desmopressin.	Approved, Investigational
Azapropazone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Desmopressin.	Withdrawn
Azelastine	The risk or severity of adverse effects can be increased when Azelastine is combined with Desmopressin.	Approved
Balsalazide	The risk or severity of adverse effects can be increased when Balsalazide is combined with Desmopressin.	Approved, Investigational
Bendazac	The risk or severity of adverse effects can be increased when Bendazac is combined with Desmopressin.	Experimental
Benorilate	The risk or severity of adverse effects can be increased when Benorilate is combined with Desmopressin.	Experimental
Benoxaprofen	The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Desmopressin.	Withdrawn
Benzydamine	The risk or severity of adverse effects can be increased when Benzydamine is combined with Desmopressin.	Approved
Bevonium	The risk or severity of adverse effects can be increased when Bevonium is combined with Desmopressin.	Experimental
Bezitramide	The risk or severity of adverse effects can be increased when Bezitramide is combined with Desmopressin.	Experimental, Illicit, Withdrawn
Bromfenac	The risk or severity of adverse effects can be increased when Bromfenac is combined with Desmopressin.	Approved
Bucillamine	The risk or severity of adverse effects can be increased when Bucillamine is combined with Desmopressin.	Investigational
Bufexamac	The risk or severity of adverse effects can be increased when Bufexamac is combined with Desmopressin.	Approved, Experimental
Bumadizone	The risk or severity of adverse effects can be increased when Bumadizone is combined with Desmopressin.	Experimental
Buprenorphine	The risk or severity of adverse effects can be increased when Buprenorphine is combined with Desmopressin.	Approved, Illicit, Investigational, Vet Approved
Butorphanol	The risk or severity of adverse effects can be increased when Butorphanol is combined with Desmopressin.	Approved, Illicit, Vet Approved
Carbamazepine	The risk or severity of adverse effects can be increased when Carbamazepine is combined with Desmopressin.	Approved, Investigational
Carbaspirin calcium	The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Desmopressin.	Experimental, Investigational
Carfentanil	The risk or severity of adverse effects can be increased when Carfentanil is combined with Desmopressin.	Illicit, Investigational, Vet Approved
Carprofen	The risk or severity of adverse effects can be increased when Carprofen is combined with Desmopressin.	Approved, Vet Approved, Withdrawn
Castanospermine	The risk or severity of adverse effects can be increased when Castanospermine is combined with Desmopressin.	Experimental
Celecoxib	The risk or severity of adverse effects can be increased when Celecoxib is combined with Desmopressin.	Approved, Investigational
Chloroquine	The risk or severity of adverse effects can be increased when Chloroquine is combined with Desmopressin.	Approved, Investigational, Vet Approved
Chlorpromazine	The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Desmopressin.	Approved, Investigational, Vet Approved
Choline magnesium trisalicylate	The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Desmopressin.	Approved
Citalopram	The risk or severity of adverse effects can be increased when Citalopram is combined with Desmopressin.	Approved
Clomipramine	The risk or severity of adverse effects can be increased when Clomipramine is combined with Desmopressin.	Approved, Investigational, Vet Approved
Clonixin	The risk or severity of adverse effects can be increased when Clonixin is combined with Desmopressin.	Approved
Codeine	The risk or severity of adverse effects can be increased when Codeine is combined with Desmopressin.	Approved, Illicit
Curcumin	The risk or severity of adverse effects can be increased when Curcumin is combined with Desmopressin.	Approved, Investigational
Cyclobenzaprine	The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desmopressin.	Approved
Dapoxetine	The risk or severity of adverse effects can be increased when Dapoxetine is combined with Desmopressin.	Investigational
Demeclocycline	The therapeutic efficacy of Desmopressin can be decreased when used in combination with Demeclocycline.	Approved
Desipramine	The risk or severity of adverse effects can be increased when Desipramine is combined with Desmopressin.	Approved, Investigational
Desvenlafaxine	The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Desmopressin.	Approved, Investigational
Dextromoramide	The risk or severity of adverse effects can be increased when Dextromoramide is combined with Desmopressin.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desmopressin.	Approved, Illicit, Investigational, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Dezocine is combined with Desmopressin.	Approved, Investigational
Dibenzepin	The risk or severity of adverse effects can be increased when Dibenzepin is combined with Desmopressin.	Experimental
Diclofenac	The risk or severity of adverse effects can be increased when Diclofenac is combined with Desmopressin.	Approved, Vet Approved
Difenpiramide	The risk or severity of adverse effects can be increased when Difenpiramide is combined with Desmopressin.	Experimental
Diflunisal	The risk or severity of adverse effects can be increased when Diflunisal is combined with Desmopressin.	Approved, Investigational
Dihydrocodeine	The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Desmopressin.	Approved, Illicit
Dihydroetorphine	The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Desmopressin.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Desmopressin.	Experimental, Illicit
Diphenoxylate	The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desmopressin.	Approved, Illicit
Dosulepin	The risk or severity of adverse effects can be increased when Dosulepin is combined with Desmopressin.	Approved
Doxepin	The risk or severity of adverse effects can be increased when Doxepin is combined with Desmopressin.	Approved, Investigational
DPDPE	The risk or severity of adverse effects can be increased when DPDPE is combined with Desmopressin.	Experimental
Droxicam	The risk or severity of adverse effects can be increased when Droxicam is combined with Desmopressin.	Withdrawn
Duloxetine	The risk or severity of adverse effects can be increased when Duloxetine is combined with Desmopressin.	Approved
Duvelisib	The risk or severity of adverse effects can be increased when Duvelisib is combined with Desmopressin.	Investigational
E-6201	The risk or severity of adverse effects can be increased when E-6201 is combined with Desmopressin.	Investigational
Epirizole	The risk or severity of adverse effects can be increased when Epirizole is combined with Desmopressin.	Approved
Escitalopram	The risk or severity of adverse effects can be increased when Escitalopram is combined with Desmopressin.	Approved, Investigational
Esmirtazapine	The risk or severity of adverse effects can be increased when Esmirtazapine is combined with Desmopressin.	Investigational
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Desmopressin.	Approved, Investigational
Ethenzamide	The risk or severity of adverse effects can be increased when Ethenzamide is combined with Desmopressin.	Experimental
Ethylmorphine	The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Desmopressin.	Approved, Illicit
Etodolac	The risk or severity of adverse effects can be increased when Etodolac is combined with Desmopressin.	Approved, Investigational, Vet Approved
Etofenamate	The risk or severity of adverse effects can be increased when Etofenamate is combined with Desmopressin.	Approved, Investigational
Etoperidone	The risk or severity of adverse effects can be increased when Etoperidone is combined with Desmopressin.	Withdrawn
Etoricoxib	The risk or severity of adverse effects can be increased when Etoricoxib is combined with Desmopressin.	Approved, Investigational
Etorphine	The risk or severity of adverse effects can be increased when Etorphine is combined with Desmopressin.	Illicit, Vet Approved
Evening primrose oil	The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Desmopressin.	Approved, Investigational
Exisulind	The risk or severity of adverse effects can be increased when Exisulind is combined with Desmopressin.	Investigational
Felbinac	The risk or severity of adverse effects can be increased when Felbinac is combined with Desmopressin.	Experimental
Fenbufen	The risk or severity of adverse effects can be increased when Fenbufen is combined with Desmopressin.	Approved
Fenoprofen	The risk or severity of adverse effects can be increased when Fenoprofen is combined with Desmopressin.	Approved
Fentanyl	The risk or severity of adverse effects can be increased when Fentanyl is combined with Desmopressin.	Approved, Illicit, Investigational, Vet Approved
Fentiazac	The risk or severity of adverse effects can be increased when Fentiazac is combined with Desmopressin.	Experimental
Feprazone	The risk or severity of adverse effects can be increased when Feprazone is combined with Desmopressin.	Experimental
Ferulic acid	The risk or severity of adverse effects can be increased when Ferulic acid is combined with Desmopressin.	Experimental
Floctafenine	The risk or severity of adverse effects can be increased when Floctafenine is combined with Desmopressin.	Approved, Withdrawn
Flunixin	The risk or severity of adverse effects can be increased when Flunixin is combined with Desmopressin.	Vet Approved
Flunoxaprofen	The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Desmopressin.	Experimental
Fluoxetine	The risk or severity of adverse effects can be increased when Fluoxetine is combined with Desmopressin.	Approved, Vet Approved
Flurbiprofen	The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Desmopressin.	Approved, Investigational
Fluvoxamine	The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desmopressin.	Approved, Investigational
Guacetisal	The risk or severity of adverse effects can be increased when Guacetisal is combined with Desmopressin.	Experimental
Heroin	The risk or severity of adverse effects can be increased when Heroin is combined with Desmopressin.	Approved, Illicit, Investigational
Higenamine	The risk or severity of adverse effects can be increased when Higenamine is combined with Desmopressin.	Investigational
Hydrocodone	The risk or severity of adverse effects can be increased when Hydrocodone is combined with Desmopressin.	Approved, Illicit
Hydromorphone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Desmopressin.	Approved, Illicit
Ibuprofen	The risk or severity of adverse effects can be increased when Ibuprofen is combined with Desmopressin.	Approved
Ibuproxam	The risk or severity of adverse effects can be increased when Ibuproxam is combined with Desmopressin.	Withdrawn
Icatibant	The risk or severity of adverse effects can be increased when Icatibant is combined with Desmopressin.	Approved, Investigational
Imidazole salicylate	The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Desmopressin.	Experimental
Imipramine	The risk or severity of adverse effects can be increased when Imipramine is combined with Desmopressin.	Approved
Indalpine	The risk or severity of adverse effects can be increased when Indalpine is combined with Desmopressin.	Investigational, Withdrawn
Indobufen	The risk or severity of adverse effects can be increased when Indobufen is combined with Desmopressin.	Investigational
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Desmopressin.	Approved, Investigational
Indoprofen	The risk or severity of adverse effects can be increased when Indoprofen is combined with Desmopressin.	Withdrawn
Iprindole	The risk or severity of adverse effects can be increased when Iprindole is combined with Desmopressin.	Experimental
Isoxicam	The risk or severity of adverse effects can be increased when Isoxicam is combined with Desmopressin.	Withdrawn
Kebuzone	The risk or severity of adverse effects can be increased when Kebuzone is combined with Desmopressin.	Experimental
Ketobemidone	The risk or severity of adverse effects can be increased when Ketobemidone is combined with Desmopressin.	Approved, Investigational
Ketoprofen	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Desmopressin.	Approved, Vet Approved
Ketorolac	The risk or severity of adverse effects can be increased when Ketorolac is combined with Desmopressin.	Approved
Lamotrigine	The risk or severity of adverse effects can be increased when Lamotrigine is combined with Desmopressin.	Approved, Investigational
Leflunomide	The risk or severity of adverse effects can be increased when Leflunomide is combined with Desmopressin.	Approved, Investigational
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Desmopressin.	Approved, Investigational
Levomilnacipran	The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Desmopressin.	Approved, Investigational
Levorphanol	The risk or severity of adverse effects can be increased when Levorphanol is combined with Desmopressin.	Approved
Lisofylline	The risk or severity of adverse effects can be increased when Lisofylline is combined with Desmopressin.	Investigational
Lithium	The therapeutic efficacy of Desmopressin can be decreased when used in combination with Lithium.	Approved
Lofentanil	The risk or severity of adverse effects can be increased when Lofentanil is combined with Desmopressin.	Illicit
Lofepramine	The risk or severity of adverse effects can be increased when Lofepramine is combined with Desmopressin.	Experimental
Lonazolac	The risk or severity of adverse effects can be increased when Lonazolac is combined with Desmopressin.	Experimental
Lornoxicam	The risk or severity of adverse effects can be increased when Lornoxicam is combined with Desmopressin.	Approved, Investigational
Loxoprofen	The risk or severity of adverse effects can be increased when Loxoprofen is combined with Desmopressin.	Approved, Investigational
Lumiracoxib	The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Desmopressin.	Approved, Investigational
Magnesium salicylate	The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desmopressin.	Approved
Masoprocol	The risk or severity of adverse effects can be increased when Masoprocol is combined with Desmopressin.	Approved, Investigational
Meclofenamic acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desmopressin.	Approved, Vet Approved
Mefenamic acid	The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Desmopressin.	Approved
Meloxicam	The risk or severity of adverse effects can be increased when Meloxicam is combined with Desmopressin.	Approved, Vet Approved
Meptazinol	The risk or severity of adverse effects can be increased when Meptazinol is combined with Desmopressin.	Experimental
Mesalazine	The risk or severity of adverse effects can be increased when Mesalazine is combined with Desmopressin.	Approved
Metamizole	The risk or severity of adverse effects can be increased when Metamizole is combined with Desmopressin.	Approved, Investigational, Withdrawn
Methadone	The risk or severity of adverse effects can be increased when Methadone is combined with Desmopressin.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Desmopressin.	Approved, Illicit
Milnacipran	The risk or severity of adverse effects can be increased when Milnacipran is combined with Desmopressin.	Approved, Investigational
Mirtazapine	The risk or severity of adverse effects can be increased when Mirtazapine is combined with Desmopressin.	Approved
Mizoribine	The risk or severity of adverse effects can be increased when Mizoribine is combined with Desmopressin.	Investigational
Mofebutazone	The risk or severity of adverse effects can be increased when Mofebutazone is combined with Desmopressin.	Experimental
Morphine	The risk or severity of adverse effects can be increased when Morphine is combined with Desmopressin.	Approved, Investigational
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Desmopressin.	Approved, Investigational
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desmopressin.	Approved
Nabumetone	The risk or severity of adverse effects can be increased when Nabumetone is combined with Desmopressin.	Approved
Nafamostat	The risk or severity of adverse effects can be increased when Nafamostat is combined with Desmopressin.	Approved, Investigational
Naftifine	The risk or severity of adverse effects can be increased when Naftifine is combined with Desmopressin.	Approved
Nalbuphine	The risk or severity of adverse effects can be increased when Nalbuphine is combined with Desmopressin.	Approved
Naproxen	The risk or severity of adverse effects can be increased when Naproxen is combined with Desmopressin.	Approved, Vet Approved
Nefazodone	The risk or severity of adverse effects can be increased when Nefazodone is combined with Desmopressin.	Approved, Withdrawn
Nepafenac	The risk or severity of adverse effects can be increased when Nepafenac is combined with Desmopressin.	Approved, Investigational
Nicomorphine	The risk or severity of adverse effects can be increased when Nicomorphine is combined with Desmopressin.	Experimental
Nifenazone	The risk or severity of adverse effects can be increased when Nifenazone is combined with Desmopressin.	Experimental
Niflumic Acid	The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Desmopressin.	Approved
Nimesulide	The risk or severity of adverse effects can be increased when Nimesulide is combined with Desmopressin.	Approved, Investigational, Withdrawn
Nitroaspirin	The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Desmopressin.	Investigational
Normethadone	The risk or severity of adverse effects can be increased when Normethadone is combined with Desmopressin.	Approved, Illicit
Nortriptyline	The risk or severity of adverse effects can be increased when Nortriptyline is combined with Desmopressin.	Approved
Olopatadine	The risk or severity of adverse effects can be increased when Olopatadine is combined with Desmopressin.	Approved
Olsalazine	The risk or severity of adverse effects can be increased when Olsalazine is combined with Desmopressin.	Approved
Opipramol	The risk or severity of adverse effects can be increased when Opipramol is combined with Desmopressin.	Investigational
Opium	The risk or severity of adverse effects can be increased when Opium is combined with Desmopressin.	Approved, Illicit
Orgotein	The risk or severity of adverse effects can be increased when Orgotein is combined with Desmopressin.	Vet Approved
Oxaprozin	The risk or severity of adverse effects can be increased when Oxaprozin is combined with Desmopressin.	Approved
Oxycodone	The risk or severity of adverse effects can be increased when Oxycodone is combined with Desmopressin.	Approved, Illicit, Investigational
Oxymorphone	The risk or severity of adverse effects can be increased when Oxymorphone is combined with Desmopressin.	Approved, Investigational, Vet Approved
Oxyphenbutazone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desmopressin.	Approved, Withdrawn
Parecoxib	The risk or severity of adverse effects can be increased when Parecoxib is combined with Desmopressin.	Approved
Paroxetine	The risk or severity of adverse effects can be increased when Paroxetine is combined with Desmopressin.	Approved, Investigational
Parthenolide	The risk or severity of adverse effects can be increased when Parthenolide is combined with Desmopressin.	Approved, Investigational
Pentazocine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Desmopressin.	Approved, Vet Approved
Pethidine	The risk or severity of adverse effects can be increased when Pethidine is combined with Desmopressin.	Approved
Phenazocine	The risk or severity of adverse effects can be increased when Phenazocine is combined with Desmopressin.	Experimental
Phenoperidine	The risk or severity of adverse effects can be increased when Phenoperidine is combined with Desmopressin.	Experimental
Phenylbutazone	The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Desmopressin.	Approved, Vet Approved
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Desmopressin.	Approved, Investigational
Pirfenidone	The risk or severity of adverse effects can be increased when Pirfenidone is combined with Desmopressin.	Approved, Investigational
Piritramide	The risk or severity of adverse effects can be increased when Piritramide is combined with Desmopressin.	Approved, Investigational
Piroxicam	The risk or severity of adverse effects can be increased when Piroxicam is combined with Desmopressin.	Approved, Investigational
Pirprofen	The risk or severity of adverse effects can be increased when Pirprofen is combined with Desmopressin.	Experimental
Pranoprofen	The risk or severity of adverse effects can be increased when Pranoprofen is combined with Desmopressin.	Experimental, Investigational
Proglumetacin	The risk or severity of adverse effects can be increased when Proglumetacin is combined with Desmopressin.	Experimental
Propacetamol	The risk or severity of adverse effects can be increased when Propacetamol is combined with Desmopressin.	Approved, Investigational
Propyphenazone	The risk or severity of adverse effects can be increased when Propyphenazone is combined with Desmopressin.	Experimental
Proquazone	The risk or severity of adverse effects can be increased when Proquazone is combined with Desmopressin.	Experimental
Protriptyline	The risk or severity of adverse effects can be increased when Protriptyline is combined with Desmopressin.	Approved
PTC299	The risk or severity of adverse effects can be increased when PTC299 is combined with Desmopressin.	Investigational
Remifentanil	The risk or severity of adverse effects can be increased when Remifentanil is combined with Desmopressin.	Approved
Resveratrol	The risk or severity of adverse effects can be increased when Resveratrol is combined with Desmopressin.	Approved, Experimental, Investigational
Rofecoxib	The risk or severity of adverse effects can be increased when Rofecoxib is combined with Desmopressin.	Approved, Investigational, Withdrawn
Salicylamide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Desmopressin.	Approved
Salicylic acid	The risk or severity of adverse effects can be increased when Salicylic acid is combined with Desmopressin.	Approved, Investigational, Vet Approved
Salsalate	The risk or severity of adverse effects can be increased when Salsalate is combined with Desmopressin.	Approved
Semapimod	The risk or severity of adverse effects can be increased when Semapimod is combined with Desmopressin.	Investigational
Seratrodast	The risk or severity of adverse effects can be increased when Seratrodast is combined with Desmopressin.	Approved
Serrapeptase	The risk or severity of adverse effects can be increased when Serrapeptase is combined with Desmopressin.	Investigational
Sertraline	The risk or severity of adverse effects can be increased when Sertraline is combined with Desmopressin.	Approved
SRT501	The risk or severity of adverse effects can be increased when SRT501 is combined with Desmopressin.	Investigational
Sufentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Desmopressin.	Approved, Investigational
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Desmopressin.	Approved
Sulindac	The risk or severity of adverse effects can be increased when Sulindac is combined with Desmopressin.	Approved, Investigational
Suprofen	The risk or severity of adverse effects can be increased when Suprofen is combined with Desmopressin.	Approved, Withdrawn
Suxibuzone	The risk or severity of adverse effects can be increased when Suxibuzone is combined with Desmopressin.	Experimental
Tapentadol	The risk or severity of adverse effects can be increased when Tapentadol is combined with Desmopressin.	Approved
Tarenflurbil	The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Desmopressin.	Investigational
Tenidap	The risk or severity of adverse effects can be increased when Tenidap is combined with Desmopressin.	Experimental
Tenoxicam	The risk or severity of adverse effects can be increased when Tenoxicam is combined with Desmopressin.	Approved
Tepoxalin	The risk or severity of adverse effects can be increased when Tepoxalin is combined with Desmopressin.	Vet Approved
Teriflunomide	The risk or severity of adverse effects can be increased when Teriflunomide is combined with Desmopressin.	Approved
Tianeptine	The risk or severity of adverse effects can be increased when Tianeptine is combined with Desmopressin.	Approved, Investigational
Tiaprofenic acid	The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desmopressin.	Approved
Tilidine	The risk or severity of adverse effects can be increased when Tilidine is combined with Desmopressin.	Experimental
Tinoridine	The risk or severity of adverse effects can be increased when Tinoridine is combined with Desmopressin.	Investigational
Tolfenamic Acid	The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Desmopressin.	Approved, Investigational
Tolmetin	The risk or severity of adverse effects can be increased when Tolmetin is combined with Desmopressin.	Approved
Tolvaptan	The therapeutic efficacy of Desmopressin can be decreased when used in combination with Tolvaptan.	Approved
Tramadol	The risk or severity of adverse effects can be increased when Tramadol is combined with Desmopressin.	Approved, Investigational
Tranilast	The risk or severity of adverse effects can be increased when Tranilast is combined with Desmopressin.	Approved, Investigational
Tribenoside	The risk or severity of adverse effects can be increased when Tribenoside is combined with Desmopressin.	Experimental
Trimipramine	The risk or severity of adverse effects can be increased when Trimipramine is combined with Desmopressin.	Approved
Triptolide	The risk or severity of adverse effects can be increased when Triptolide is combined with Desmopressin.	Investigational
Valdecoxib	The risk or severity of adverse effects can be increased when Valdecoxib is combined with Desmopressin.	Approved, Investigational, Withdrawn
Venlafaxine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Desmopressin.	Approved
Zaltoprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desmopressin.	Approved, Investigational
Zileuton	The risk or severity of adverse effects can be increased when Zileuton is combined with Desmopressin.	Approved, Investigational, Withdrawn
Zimelidine	The risk or severity of adverse effects can be increased when Zimelidine is combined with Desmopressin.	Withdrawn
Zomepirac	The risk or severity of adverse effects can be increased when Zomepirac is combined with Desmopressin.	Withdrawn

Food Interactions

Not Available

References

Synthesis Reference

Krister Larsson, Thomas Mellbrand, Birgitta Mornstam, Jan Roschester, Jan-Ake Skoldback, "High purity desmopressin produced in large single batches." U.S. Patent US5674850, issued November, 1991.

US5674850

General References

Leissinger C, Becton D, Cornell C Jr, Cox Gill J: High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia. 2001 May;7(3):258-66. [PubMed:11380629]
Richardson DW, Robinson AG: Desmopressin. Ann Intern Med. 1985 Aug;103(2):228-39. [PubMed:3893256]
Vande Walle J, Stockner M, Raes A, Norgaard JP: Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf. 2007 Sep;2(3):232-8. [PubMed:18690973]
Agerso H, Seiding Larsen L, Riis A, Lovgren U, Karlsson MO, Senderovitz T: Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. Br J Clin Pharmacol. 2004 Oct;58(4):352-8. doi: 10.1111/j.1365-2125.2004.02175.x. [PubMed:15373927]
Lundin S, Broeders A, Melin P: Pharmacokinetic properties of the tocolytic agent [Mpa1, D-Tyr(Et)2, Thr4, Orn8]-oxytocin (antocin) in healthy volunteers. Clin Endocrinol (Oxf). 1993 Sep;39(3):369-74. [PubMed:8222299]
32. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 399-400). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
DDVAP Nasal Spray FDA Label [Link]
Stimate (desmopressin acetate) nasal spray FDA Label [Link]
UKPAR for Desmopressin acetate 100mcg and 200mcg Tablets [Link]

External Links

Human Metabolome Database: HMDB0014260
KEGG Drug: D00291
KEGG Compound: C06944
ChemSpider: 10481973
BindingDB: 50205291
ChEBI: 4450
ChEMBL: CHEMBL376685
Therapeutic Targets Database: DNC000526
PharmGKB: PA449237
RxList: RxList Drug Page
Drugs.com: Drugs.com Drug Page
Wikipedia: Desmopressin

ATC Codes

H01BA02 — Desmopressin

AHFS Codes

68:28.00 — Pituitary

FDA label

Download (1.22 MB)

MSDS

Download (26.2 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Not Available	Healthy Volunteers	1
1	Completed	Treatment	Dyspnea / Haemorrhage / Tachycardia	1
1	Completed	Treatment	High Blood Pressure (Hypertension)	1
1	Enrolling by Invitation	Diagnostic	Hemophilia A	1
2	Completed	Not Available	Cancer, Breast	1
2	Completed	Other	Colorectal Cancers / Rectal haemorrhage	1
2	Completed	Treatment	Intracerebral Hemorrhage	1
2	Completed	Treatment	Nocturia	1
2	Recruiting	Treatment	Nocturia	1
2	Terminated	Treatment	Nocturia	1
2	Unknown Status	Treatment	Postoperative Ecchymosis	1
2, 3	Terminated	Treatment	Leptospirosis	1
2, 3	Terminated	Treatment	Nocturia	1
3	Completed	Treatment	Central Diabetes Insipidus	1
3	Completed	Treatment	Nocturia	7
3	Completed	Treatment	Nocturnal Enuresis	2
3	Completed	Treatment	Primary Nocturnal Enuresis	1
3	Recruiting	Treatment	Nocturnal Enuresis / Sickle Cell Disorders	1
3	Terminated	Treatment	Nocturia / Obstructive Sleep Apnoea (OSA)	1
3	Unknown Status	Treatment	Pain / Renal Colic	1
4	Active Not Recruiting	Prevention	C.Surgical Procedure; Cardiac / Disorders, Blood Coagulation	1
4	Completed	Prevention	Blood Loss,Surgical / Hemorrhage / Postoperative Hemorrhages	1
4	Completed	Prevention	Patients Undergoing Endoscopic Sinus Surgery	1
4	Completed	Prevention	Renal Failure	1
4	Completed	Treatment	Acquired Von Willebrand Disease Secondary to Severe Aortic Stenosis / Heye´s Syndrome / Severe Aortic Stenosis	1
4	Completed	Treatment	Enuresis / Polyuria	1
4	Completed	Treatment	Nocturia	1
4	Completed	Treatment	Nocturnal Polyuria	1
4	Completed	Treatment	Primary Nocturnal Enuresis	1
4	Recruiting	Diagnostic	Monosymptomatic Nocturnal Enuresis	1
4	Recruiting	Treatment	Children With Mild Hemophilia A / Mild Haemophilia A Without Inhibitor	1
4	Recruiting	Treatment	Enuresis, Nocturnal	1
4	Terminated	Treatment	Hemorrhage / Postoperative Blood Loss	1
4	Terminated	Treatment	Parkinson's Disease (PD)	1
4	Unknown Status	Treatment	Hypothermia Induced Impairment of Primary Haemostasis	1
4	Unknown Status	Treatment	Nocturia	1
4	Unknown Status	Treatment	Nocturnal Enuresis	1
Not Available	Completed	Not Available	Head Injury Trauma Blunt	1
Not Available	Completed	Not Available	Nocturia Associated With Nocturnal Polyuria	1
Not Available	Completed	Not Available	Platelets Dysfunction	1
Not Available	Completed	Basic Science	Gender Difference in V2 Receptor Function in Response to dDAVP Infusion / Nocturia / Nocturnal Enuresis	1
Not Available	Completed	Prevention	Blood Platelet Disorders / Disorders, Blood Coagulation / Hematologic Diseases / Hypermenorrhea / Von Willebrand 's disease Type 1	1
Not Available	Completed	Screening	Diabetes Insipidus / Diabetes Insipidus, Neurohypophyseal	1
Not Available	Completed	Treatment	Coagulation Disorders / Liver Cirrhosis	1
Not Available	Completed	Treatment	Desmopressin / Hemodilution / Mild Hypothermia / NSAIDs / Platelets Dysfunction	1
Not Available	Completed	Treatment	Renal Colic	1
Not Available	Recruiting	Not Available	Nocturia	1
Not Available	Unknown Status	Not Available	Acquired Haemophilia	1
Not Available	Unknown Status	Screening	Diabetes Insipidus	1
Not Available	Unknown Status	Treatment	Idiopathic Scoliosis	1

Pharmacoeconomics

Manufacturers

Sanofi aventis us llc
Bedford laboratories div ben venue laboratories inc
Hospira inc
Teva parenteral medicines inc
Ferring pharmaceuticals inc
Bausch and lomb pharmaceuticals inc
Apotex inc richmond hill
Csl behring llc
Apotex inc etobicoke site
Teva pharmaceuticals usa
Watson laboratories inc

Packagers

Amerisource Health Services Corp.
Apotex Inc.
Arcola Laboratories
Bachem Inc.
Barr Pharmaceuticals
Bausch & Lomb Inc.
CSL Behring LLC
Ferring Pharmaceuticals Inc.
Hospira Inc.
Kaiser Foundation Hospital
Pharmacy Service Center
Physicians Total Care Inc.
Promex Medical Inc.
Rechon Life Science AB
Sanofi-Aventis Inc.
Sicor Pharmaceuticals
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
UDL Laboratories
Watson Pharmaceuticals

Dosage forms

Form	Route	Strength
Injection	Intravenous	4 ug/mL
Spray	Nasal	.1 ug/mL
Liquid	Intramuscular; Intravenous; Subcutaneous	4 mcg
Tablet, orally disintegrating	Sublingual	120 mcg
Tablet, orally disintegrating	Sublingual	240 mcg
Tablet, orally disintegrating	Sublingual	60 mcg
Solution	Nasal	.1 mg/mL
Solution	Nasal	0.1 mg
Aerosol, metered	Nasal	10 mcg
Tablet	Oral	0.1 mg
Tablet	Oral	0.2 mg
Injection, solution	Intravenous; Subcutaneous	4 ug/mL
Injection, solution	Intravenous; Subcutaneous	40 ug/10mL
Solution	Intravenous	4 ug/mL
Spray	Nasal	.1 mg/mL
Spray	Nasal	10 ug/1
Spray	Nasal	10 ug/.1mL
Tablet	Oral	.1 mg/1
Tablet	Oral	.2 mg/1
Spray, metered	Nasal	10 mcg
Tablet, orally disintegrating	Sublingual	25 mcg
Tablet, orally disintegrating	Sublingual	50 mcg
Spray, metered	Nasal	.83 ug/1
Spray, metered	Nasal	1.66 ug/1
Liquid	Intravenous; Subcutaneous	15 mcg
Spray	Nasal	150 mcg
Spray, metered	Nasal	1.5 mg/mL

Prices

Unit description	Cost	Unit
Stimate 1.5 mg/ml nasal spray	334.2USD	ml
Ddavp 0.01% nasal spray	50.76USD	ml
Ddavp 4 mcg/ml ampul	43.27USD	ml
Desmopressin 0.1 mg/ml spray	39.6USD	ml
Ddavp 0.1 mg/ml Solution	21.26USD	ml
Octostim 150 mcg/dose Metered Dose Spray	17.39USD	dose
Ddavp 4 mcg/ml	11.33USD	ml
Desmopressin ac 4 mcg/ml amp	7.28USD	ml
Desmopressin ac 4 mcg/ml vial	7.08USD	ml
Ddavp 0.2 mg tablet	6.43USD	tablet
Ddavp 0.1 mg tablet	4.47USD	tablet
Desmopressin acetate 0.2 mg tablet	4.44USD	tablet
Desmopressin acetate 0.1 mg tablet	3.08USD	tablet
Ddavp 0.2 mg Tablet	2.98USD	tablet
Ddavp 10 mcg/dose Metered Dose Spray	2.13USD	dose
Apo-Desmopressin 0.2 mg Tablet	1.67USD	tablet
Novo-Desmopressin 0.2 mg Tablet	1.67USD	tablet
Pms-Desmopressin 0.2 mg Tablet	1.67USD	tablet
Ddavp 0.1 mg Tablet	1.49USD	tablet
Apo-Desmopressin 10 mcg/dose Metered Dose Spray	1.48USD	dose
Apo-Desmopressin 0.1 mg Tablet	0.83USD	tablet
Novo-Desmopressin 0.1 mg Tablet	0.83USD	tablet
Pms-Desmopressin 0.1 mg Tablet	0.83USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US7022340	No	2003-04-30	2023-04-30
US5500413	No	1993-06-29	2013-06-29
CA2484724	No	2007-01-16	2023-05-07
CA2486833	No	2005-08-02	2024-04-30
US9539302	No	2010-06-15	2030-06-15
US7799761	No	2004-09-26	2024-09-26
US7405203	No	2003-05-06	2023-05-06
US7579321	No	2003-05-06	2023-05-06

Properties

State

Solid

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.11 mg/mL	ALOGPS
logP	-1	ALOGPS
logP	-6.1	ChemAxon
logS	-4	ALOGPS
pKa (Strongest Acidic)	9.5	ChemAxon
pKa (Strongest Basic)	11.77	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	15	ChemAxon
Hydrogen Donor Count	14	ChemAxon
Polar Surface Area	435.41 Å²	ChemAxon
Rotatable Bond Count	19	ChemAxon
Refractivity	279.78 m³·mol^-1	ChemAxon
Polarizability	104.7 Å³	ChemAxon
Number of Rings	4	ChemAxon
Bioavailability	0	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.7979
Blood Brain Barrier	-	0.8866
Caco-2 permeable	-	0.7612
P-glycoprotein substrate	Substrate	0.8242
P-glycoprotein inhibitor I	Non-inhibitor	0.7864
P-glycoprotein inhibitor II	Non-inhibitor	0.9237
Renal organic cation transporter	Non-inhibitor	0.5915
CYP450 2C9 substrate	Non-substrate	0.7833
CYP450 2D6 substrate	Non-substrate	0.7901
CYP450 3A4 substrate	Non-substrate	0.5497
CYP450 1A2 substrate	Non-inhibitor	0.8383
CYP450 2C9 inhibitor	Non-inhibitor	0.7906
CYP450 2D6 inhibitor	Non-inhibitor	0.8735
CYP450 2C19 inhibitor	Non-inhibitor	0.765
CYP450 3A4 inhibitor	Non-inhibitor	0.7663
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9331
Ames test	Non AMES toxic	0.6679
Carcinogenicity	Non-carcinogens	0.8428
Biodegradation	Not ready biodegradable	0.9445
Rat acute toxicity	2.7183 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.83
hERG inhibition (predictor II)	Inhibitor	0.6036

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Taxonomy

Description: This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.
Kingdom: Organic compounds
Super Class: Organic acids and derivatives
Class: Carboxylic acids and derivatives
Sub Class: Amino acids, peptides, and analogues
Direct Parent: Oligopeptides
Alternative Parents: Cyclic peptides / Arginine and derivatives / Proline and derivatives / N-acyl-alpha amino acids and derivatives / Macrolactams / Alpha amino acid amides / Pyrrolidinecarboxamides / N-acylpyrrolidines / 1-hydroxy-2-unsubstituted benzenoids / Benzene and substituted derivatives
show 14 more
Substituents: Alpha-oligopeptide / Cyclic alpha peptide / Arginine or derivatives / N-acyl-alpha amino acid or derivatives / Proline or derivatives / Macrolactam / Alpha-amino acid amide / N-substituted-alpha-amino acid / Alpha-amino acid or derivatives / N-acylpyrrolidine
show 30 more
Molecular Framework: Aromatic heteromonocyclic compounds
External Descriptors: Not Available

Targets

Details1. Vasopressin V2 receptor

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Agonist

General Function: Vasopressin receptor activity
Specific Function: Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Involved in renal water reabsorption.
Gene Name: AVPR2
Uniprot ID: P30518
Uniprot Name: Vasopressin V2 receptor
Molecular Weight: 40278.57 Da

References

Del Tredici AL, Vanover KE, Knapp AE, Bertozzi SM, Nash NR, Burstein ES, Lameh J, Currier EA, Davis RE, Brann MR, Mohell N, Olsson R, Piu F: Identification of novel selective V2 receptor non-peptide agonists. Biochem Pharmacol. 2008 Oct 30;76(9):1134-41. doi: 10.1016/j.bcp.2008.08.004. Epub 2008 Aug 12. [PubMed:18761325]
Slusarz MJ, Slusarz R, Ciarkowski J: Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system. Biopolymers. 2006 Apr 5;81(5):321-38. [PubMed:16333859]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Details2. Vasopressin V1a receptor

Kind: Protein
Organism: Human
Pharmacological action: Yes

General Function: Vasopressin receptor activity
Specific Function: Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system. Has been involved in social behavi...
Gene Name: AVPR1A
Uniprot ID: P37288
Uniprot Name: Vasopressin V1a receptor
Molecular Weight: 46799.105 Da

References

Loichot C, Cazaubon C, De Jong W, Helwig JJ, Nisato D, Imbs JL, Barthelmebs M: Nitric oxide, but not vasopressin V2 receptor-mediated vasodilation, modulates vasopressin-induced renal vasoconstriction in rats. Naunyn Schmiedebergs Arch Pharmacol. 2000 Mar;361(3):319-26. [PubMed:10731046]
Mechaly I, Laurent F, Portet K, Serrano J, Cros G: Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol. 1999 Nov 3;383(3):287-90. [PubMed:10594321]
Barthelmebs M, Krieger JP, Grima M, Nisato D, Imbs JL: Vascular effects of [Arg8]vasopressin in the isolated perfused rat kidney. Eur J Pharmacol. 1996 Oct 31;314(3):325-32. [PubMed:8957254]
Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004 Dec;11(4):871-85. [PubMed:15613460]

Details3. Vasopressin V1b receptor

Kind: Protein
Organism: Human
Pharmacological action: Yes

General Function: Vasopressin receptor activity
Specific Function: Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system.
Gene Name: AVPR1B
Uniprot ID: P47901
Uniprot Name: Vasopressin V1b receptor
Molecular Weight: 46970.345 Da

References

Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004 Dec;11(4):871-85. [PubMed:15613460]
Dinan TG, O'Brien S, Lavelle E, Scott LV: Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression. Psychol Med. 2004 Jan;34(1):169-72. [PubMed:14971638]
Craighead M, Milne R, Campbell-Wan L, Watson L, Presland J, Thomson FJ, Marston HM, Macsweeney CP: Characterization of a novel and selective V1B receptor antagonist. Prog Brain Res. 2008;170:527-35. doi: 10.1016/S0079-6123(08)00440-8. [PubMed:18655906]

Enzymes

Details1. Prostaglandin G/H synthase 1

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Inducer

General Function: Prostaglandin-endoperoxide synthase activity
Specific Function: Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name: PTGS1
Uniprot ID: P23219
Uniprot Name: Prostaglandin G/H synthase 1
Molecular Weight: 68685.82 Da

References

Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, Nielsen S: Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol. 2005 May;288(5):F1053-68. Epub 2005 Jan 11. [PubMed:15644490]

Details2. Prostaglandin G/H synthase 2

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Inducer

General Function: Prostaglandin-endoperoxide synthase activity
Specific Function: Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name: PTGS2
Uniprot ID: P35354
Uniprot Name: Prostaglandin G/H synthase 2
Molecular Weight: 68995.625 Da

References

Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, Nielsen S: Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol. 2005 May;288(5):F1053-68. Epub 2005 Jan 11. [PubMed:15644490]

Drug created on June 13, 2005 07:24 / Updated on April 23, 2018 23:16

Desmopressin

Identification

Structure for DB00035 (Desmopressin)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Targets

References

References

References

Enzymes

References

References